NGL Fine Chem Ltd

NGL Fine Chem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

NGL Fine Chem Ltd

₹ 1,881 1.03%
11 Dec 3:56 p.m.
nglfinechem.com BSE: 524774 NSE: NGLFINE
About

Established in 1981, NGL Fine-Chem Limited manufactures human and veterinary bulk drugs, intermediates, and formulations. It primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters [1]

Key Points

Product Portfolio FY24
Presently, Veterinary APIs are the main product of the company which account for 89% of its revenues, followed by Veterinary Formulations (5%), Human APIs (3%), and Intermediates (3%).[1] The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms.[2]

Website BSE NSE
  • Market Cap ₹ 1,163 Cr.
  • Current Price ₹ 1,881
  • High / Low ₹ 2,824 / 1,702
  • Stock P/E 30.9
  • Book Value ₹ 452
  • Dividend Yield 0.09 %
  • ROCE 18.9 %
  • ROE 15.8 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Earnings include an other income of Rs.20.0 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE SmallCap BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
78 81 78 64 65 70 74 69 79 85 96 88 91
62 69 68 63 60 62 62 62 66 74 83 82 81
Operating Profit 17 12 10 0 5 7 12 8 13 11 13 6 11
OPM % 21% 15% 13% 0% 7% 11% 16% 11% 17% 13% 13% 7% 12%
5 4 2 3 4 3 1 4 4 4 4 6 5
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 2 2 2 2 2 2 2 2 2
Profit before tax 19 14 10 1 7 8 11 9 15 13 14 10 13
Tax % 26% 23% 22% 24% 26% 25% 23% 15% 24% 30% 24% 22% 25%
14 11 8 1 5 6 9 8 11 9 11 8 10
EPS in Rs 22.97 17.56 12.72 0.83 8.03 9.86 13.81 12.64 17.76 14.41 17.56 12.67 16.25
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
56 79 88 96 100 114 153 152 258 319 275 329 360
48 68 73 74 74 92 121 129 181 253 246 284 319
Operating Profit 8 11 15 22 25 22 32 23 77 66 29 45 40
OPM % 14% 14% 17% 23% 26% 19% 21% 15% 30% 21% 10% 14% 11%
0 -1 2 0 1 3 4 1 9 13 8 16 20
Interest 1 2 2 2 1 2 3 3 2 2 2 2 2
Depreciation 2 2 3 3 3 5 6 7 7 8 8 8 9
Profit before tax 4 7 13 18 23 18 28 14 76 69 27 51 50
Tax % 35% 32% 35% 36% 35% 29% 27% 26% 27% 24% 24% 24%
3 5 8 11 15 13 20 11 55 52 20 39 38
EPS in Rs 4.71 7.33 13.48 18.45 24.10 20.38 32.58 17.16 89.79 84.57 32.57 62.35 60.89
Dividend Payout % -0% -0% -0% -0% -0% -0% 5% 10% 2% 2% 5% 3%
Compounded Sales Growth
10 Years: 15%
5 Years: 17%
3 Years: 8%
TTM: 23%
Compounded Profit Growth
10 Years: 23%
5 Years: 14%
3 Years: -11%
TTM: 13%
Stock Price CAGR
10 Years: 37%
5 Years: 35%
3 Years: -10%
1 Year: -7%
Return on Equity
10 Years: 22%
5 Years: 21%
3 Years: 17%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 17 21 30 41 56 69 89 98 152 203 222 260 276
13 17 13 14 23 27 27 28 16 30 32 34 49
14 15 21 19 20 31 23 26 34 41 30 56 60
Total Liabilities 47 56 67 78 102 129 142 156 206 278 288 353 389
18 19 17 24 25 56 61 61 58 59 59 60 65
CWIP -0 -0 1 2 16 3 -0 -0 1 6 26 46 61
Investments 0 0 2 3 6 6 9 14 33 32 43 57 82
30 37 46 49 55 63 73 80 115 180 159 190 181
Total Assets 47 56 67 78 102 129 142 156 206 278 288 353 389

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-0 -0 8 8 10 22 9 20 27 13 32 11
-3 -4 -3 -10 -10 -21 -10 -19 -24 -13 -24 -17
4 3 -4 2 -0 -0 -0 -1 -1 -1 -1 -1
Net Cash Flow 1 -1 1 0 -0 1 -1 -0 2 -1 7 -7

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 100 110 107 123 110 89 79 63 53 74 86 92
Inventory Days 126 77 106 90 114 134 106 154 132 133 69 99
Days Payable 148 105 150 122 139 187 92 114 94 84 59 110
Cash Conversion Cycle 78 82 63 91 85 35 93 103 91 124 97 82
Working Capital Days 88 88 77 96 85 54 107 98 78 116 104 106
ROCE % 19% 24% 29% 37% 34% 22% 28% 15% 52% 35% 12% 19%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
73.81% 73.81% 73.81% 73.81% 73.81% 73.53% 73.53% 73.06% 73.06% 72.74% 72.74% 72.74%
0.00% 0.01% 0.05% 0.05% 0.00% 0.00% 0.00% 0.02% 0.04% 0.10% 0.03% 0.02%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
26.19% 26.18% 26.14% 26.13% 26.19% 26.47% 26.46% 26.93% 26.91% 27.16% 27.24% 27.25%
No. of Shareholders 15,69517,06818,04218,50418,44018,28717,06617,62316,41015,04114,60814,575

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls